AR131668A1 - Composición inyectable, formulación farmacéutica que incluye la misma, y método para preparar la composición - Google Patents
Composición inyectable, formulación farmacéutica que incluye la misma, y método para preparar la composiciónInfo
- Publication number
- AR131668A1 AR131668A1 ARP240100149A ARP240100149A AR131668A1 AR 131668 A1 AR131668 A1 AR 131668A1 AR P240100149 A ARP240100149 A AR P240100149A AR P240100149 A ARP240100149 A AR P240100149A AR 131668 A1 AR131668 A1 AR 131668A1
- Authority
- AR
- Argentina
- Prior art keywords
- preparing
- composition
- sbe
- pharmaceutical formulation
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biochemistry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20230013947 | 2023-02-01 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR131668A1 true AR131668A1 (es) | 2025-04-16 |
Family
ID=92024104
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP240100149A AR131668A1 (es) | 2023-02-01 | 2024-01-23 | Composición inyectable, formulación farmacéutica que incluye la misma, y método para preparar la composición |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP4658244A1 (https=) |
| JP (1) | JP2026505092A (https=) |
| KR (1) | KR20240121186A (https=) |
| CN (1) | CN118415999A (https=) |
| AR (1) | AR131668A1 (https=) |
| AU (1) | AU2024215883A1 (https=) |
| CL (1) | CL2025002270A1 (https=) |
| CO (1) | CO2025011347A2 (https=) |
| DO (1) | DOP2025000185A (https=) |
| IL (1) | IL322431A (https=) |
| JO (1) | JOP20250189A1 (https=) |
| MX (1) | MX2025008735A (https=) |
| PE (1) | PE20252396A1 (https=) |
| TW (1) | TW202432120A (https=) |
| WO (1) | WO2024161316A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120827558A (zh) * | 2024-04-19 | 2025-10-24 | 丽珠医药集团股份有限公司 | 咪唑并[1,2-a]吡啶衍生物药物组合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1682133A1 (en) * | 2003-11-03 | 2006-07-26 | AstraZeneca AB | Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux |
| AR051041A1 (es) * | 2004-10-04 | 2006-12-13 | Altana Pharma Ag | Bencimidazoles triciclicos condensados |
| FI20086158A0 (fi) * | 2008-12-03 | 2008-12-03 | Mikael Dahlstroem | Imidatsopyridiinijohdannaiset |
| GB0906470D0 (en) * | 2009-04-15 | 2009-05-20 | Astex Therapeutics Ltd | New compounds |
| KR101777971B1 (ko) * | 2016-07-05 | 2017-09-12 | 제일약품주식회사 | 이미다조[1,2-a]피리딘 유도체, 이의 제조방법 및 이의 용도 |
-
2023
- 2023-11-20 TW TW112144715A patent/TW202432120A/zh unknown
- 2023-11-29 CN CN202311609051.XA patent/CN118415999A/zh active Pending
-
2024
- 2024-01-23 AR ARP240100149A patent/AR131668A1/es unknown
- 2024-01-31 PE PE2025001666A patent/PE20252396A1/es unknown
- 2024-01-31 AU AU2024215883A patent/AU2024215883A1/en active Pending
- 2024-01-31 KR KR1020240014951A patent/KR20240121186A/ko active Pending
- 2024-01-31 IL IL322431A patent/IL322431A/en unknown
- 2024-01-31 EP EP24749813.2A patent/EP4658244A1/en active Pending
- 2024-01-31 WO PCT/IB2024/050869 patent/WO2024161316A1/en not_active Ceased
- 2024-01-31 JP JP2025544851A patent/JP2026505092A/ja active Pending
-
2025
- 2025-07-25 MX MX2025008735A patent/MX2025008735A/es unknown
- 2025-07-28 JO JOJO/P/2025/0189A patent/JOP20250189A1/ar unknown
- 2025-07-30 CL CL2025002270A patent/CL2025002270A1/es unknown
- 2025-07-31 DO DO2025000185A patent/DOP2025000185A/es unknown
- 2025-08-22 CO CONC2025/0011347A patent/CO2025011347A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2025011347A2 (es) | 2025-09-18 |
| IL322431A (en) | 2025-09-01 |
| KR20240121186A (ko) | 2024-08-08 |
| AU2024215883A1 (en) | 2025-07-31 |
| JP2026505092A (ja) | 2026-02-10 |
| CN118415999A (zh) | 2024-08-02 |
| MX2025008735A (es) | 2025-11-03 |
| DOP2025000185A (es) | 2026-02-15 |
| EP4658244A1 (en) | 2025-12-10 |
| CL2025002270A1 (es) | 2025-10-03 |
| TW202432120A (zh) | 2024-08-16 |
| JOP20250189A1 (ar) | 2025-07-28 |
| PE20252396A1 (es) | 2025-10-10 |
| WO2024161316A1 (en) | 2024-08-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20181802A1 (es) | Derivados de 4-amino-2-(1h-pirazolo[3,4-b]piridin-3-il)-6-oxo-6,7-dihidro-5h-pirrolo[2,3-d]pirimidina y los respectivos (1h-indazol-3-il) derivados como moduladores cgmp para el tratamiento de enfermedades cardiovasculares | |
| PE20180203A1 (es) | Procedimiento para la preparacion de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}metilcarbamato de metilo y su purificacion para su uso como principio activo farmaceutico | |
| AR110986A2 (es) | Composiciones de ecteinascidina, formulaciones liofilizadas, método de preparación y uso | |
| HRP20211057T1 (hr) | Formulacija implantata od risperidona i/ili paliperidona | |
| CO6551707A2 (es) | Procedimiento para la preparaciçon de {4.6-diamino-2[1-2(2-fluorobencil)-1h- pirazolo [3.4-b]piridin -3-il] pirimidin -5-il} carbamato de metilo y su purificación para el uso como principio activo farmacéutico | |
| CO6311052A2 (es) | Una microemulsion que comprende un ingrediente activo, un solvente y un surfactante no ionico y proceso para su preparación | |
| CR20110338A (es) | Formulaciones de imiquimod de baja concentración de dosis y regimenes de dosis de corta duración para tratar queratosis actínica | |
| MX2010010647A (es) | Proceso para preparar formulaciones de dabigatran para administracion oral. | |
| DOP2025000185A (es) | Composición inyectable, formulación farmacéutica que incluye la misma y método para preparar la composición | |
| UY28271A1 (es) | Compuestos químicos | |
| DOP2013000090A (es) | HIDRATO DE TARTRATO DE 1-{(2S)-2-AMINO-4-{2,4- BIS(TRIFUOROMETIL)-5,8-DI-HIDROPIRIDO{3,4-d} PIRIMIDIN-7 (6H)-IL}-4-OXOBUTIL}-5,5-DIFLUORO-PIRIDIN-2-ONA | |
| NO20090171L (no) | Substituerte aminopyrazolpyridiner og salter derav, fremgangsmate for fremstilling av slike, og farmasoytiske preparater inneholdende slike | |
| AR047993A1 (es) | Composicion farmaceutica que comprende pimobendano | |
| CL2009000246A1 (es) | Compuestos derivados de 1h-imidazo[4,5-b]piridin-2-ol; moduladores de la contraccion sarcomero; composicion farmaceutica que comprende; kit farmaceutico; y uso en el tratamiento de enfermedades neuromusculares, tales como atrofia, fatiga, claudicacion, en entre otras. | |
| BRPI0508579A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| UY28366A1 (es) | Compuestos químicos | |
| EA201201662A1 (ru) | Дизамещенные тетрагидрофуранильные соединения в качестве антагонистов брадикининового рецептора в1 | |
| CY1109541T1 (el) | Φαρμακευτικη συνταγοποιηση για την θεραπεια οστεοαρθριτιδας η οποια περιεχει κλοδρονικο οξυ και υαλουρονικο οξυ | |
| AR086448A1 (es) | Composicion farmaceutica que comprende drotaverina | |
| PE20050414A1 (es) | Formulacion farmaceutica oral que comprende un antagonista de la bomba de protones y un excipiente basico | |
| AR074724A1 (es) | Sal de citrato 11-(2-pirrolidin-1-il-etoxi)-14,19-dioxa-5,7,26-triaza-tetraciclo (19.3.1.1(2,6).1(8,12) heptacosa-1-(25),2(26),3,5,8,10,12 (27),16,21,23-decaeno | |
| HRP20200472T1 (hr) | Liječenje alopecije areate | |
| WO2013078396A3 (en) | Radiation-sterilized biodegradable drug delivery compositions | |
| ZA202301927B (en) | Phytonadione compositions | |
| CO2025011348A2 (es) | Formulación farmacéutica, método de preparación para la misma y composición de tableta |